Defibrotide sodium

USDailyMed:Defibrotide AU:D B01AX01(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 83712-60-1Y DBSALT001719YDB04932 none L7CHH2B2J0 D07423Y ChEMBL3707226ChEMBL2108396 Defibrotide, sold under the brand nameDefitelio, is a mixture of single-strandedoligonucleotidesthat is purified from theintestinal mucosaof pigs.‍‍‍‍‍‍​​​‍​​​​​​ It is used to treatveno-occlusive diseaseof the liver of people having had abone marrow transplant, with different limitations in the US and the European Union. It works by protecting the cells lining blood vessels in the liver and preventingblood clotting; the way it does this is not well understood. The most common side effects include abnormally low blood pressure (hypotension), diarrhea, vomiting, nausea and nosebleeds (epistaxis). Serious potential side effects that were identified include bleeding (hemorrhage) and allergic reactions. Defibrotide should not be used in people who are having bleeding complications or who are taking blood thinners or other medicines that reduce the body's ability to form clots.Use of the drug is generally limited by a strong risk of life-threatening bleeding in the brain, eyes, lungs, gastrointestinal tract, urinary tract, and nose. Some people have hypersensitivity reactions. Defibrotide was approved for medical use in the European Union in October 2013, in the United States in March 2016, and in Australia in July 2020.Defibrotide is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition.